Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Prezista

PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 54–55

HOS-116512 · Präparat HOS-094447

54  Nevirapine nevirapine AUC ↑ 27% PREZISTA co-administered with 200 mg twice daily nevirapine Cmin ↑ 47% low dose ritonavir and nevirapine nevirapine Cmax ↑ 18% can be used without dose # darunavir: concentrations were adjustments. consistent with historical data (↑ nevirapine from CYP3A inhibition) Rilpivirine rilpivirine AUC ↑ 130% PREZISTA co-administered with 150 mg once daily rilpivirine Cmin ↑ 178% low dose ritonavir and rilpivirine rilpivirine Cmax ↑ 79% can be used without dose darunavir AUC ↔ adjustments. darunavir Cmin ↓ 11% darunavir Cmax ↔ HIV Protease inhibitors (PIs) - without additional co-administration of low dose ritonavir† Atazanavir atazanavir AUC ↔ PREZISTA co-administered with 300 mg once daily atazanavir Cmin ↑ 52% low dose ritonavir and atazanavir atazanavir Cmax ↓ 11% can be used without dose # darunavir AUC ↔ adjustments. # darunavir Cmin ↔ # darunavir Cmax ↔

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) rilpivirine (HOS-088090) nevirapine (HOS-088064) ritonavir (HOS-084521)